Drugs / AZD2184
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT00838877 | Jan → Oct 2009 | Alzheimer disease | AstraZeneca | Completed | No outcome recorded |
| Phase 1 | NCT00692705 | Jan → Dec 2008 | Alzheimer disease | AstraZeneca | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AZD2184 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00838877 ↗ |
| Known as | (11C)AZD2184 | “Open Label Positron Emission Tomography (PET) Study With [11C]AZD2995 and [11C]AZD2184, Candidate PET Ligands for β Amyloid” NCT00692705 ↗ |
| Modality | Diagnostic / imaging agent | “Candidate PET Ligands” NCT00692705 ↗ |
| Route | Intravenous | “Single dose of i.v solution.” NCT00692705 ↗ |